AzTrials
AzTrials

Pain, PostoperativeEarly Phase 1NCT03243032

Pre-Emptive Analgesia in Dental Implant Surgery

A Early Phase 1 study testing Ibuprofen 600 mg and Local anesthetic Group 1 in people with Pain, Postoperative, run by Satheesh Elangovan at 1 site in United States.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

To determine the clinical effectiveness of combined use of pre-emptive analgesia and long acting anesthesia for pain suppression following dental implant surgery as measured by a validated numerical rating scale and the information related to consumption of post-operative medications. Read more about this study

Who is it for?
Ages 18 to 64 yearsHealthy volunteers can take part
Conditions the study is for
Pain, Postoperative
What is being tested?
Ibuprofen 600 mg and Local anesthetic Group 1
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
0 participants
Where
1 siteUnited States
Study dates
6 Oct 2017to 6 Nov 2017
Phase
Early Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 64 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Adult patients 18 years of age and under 65 years of age
  • ASA Type I \& II
  • Single tooth edentulous site requiring dental implant placement without any additional bone or soft tissue augmentation at the time of implant placement
  • Patients not requiring use of any form of sedation for dental implant surgery (nitrous, oral or IV sedation)

Who cannot join

  • Hypersensitivity to NSAIDs, salicylates, or microcrystalline cellulose NF (Avicel PH 105)
  • Liver disease
  • Renal disease
  • Hypertension and taking angiotensin-converting-enzyme inhibitors and/or diuretics
  • Significant respiratory conditions including acute or severe asthma.
  • Cardiovascular disease that will prevent the patient from going through the surgical procedure or consuming the required medications: cardiac disease, cardiomyopathy, cardiac arrhythmias, coronary heart disease, acute MI, angina, history of MI, coronary artery bypass grafting (CABG), Aspirin intake, peripheral vascular disease, cerebral vascular disease (stroke, TIA)
Show all 17Show fewer
  • Gastrointestinal disease including irritable bowel disease and gastric ulcers
  • Hematological diseases (coagulopathy, hemophilia or thrombocytopenia)
  • Pregnancy/lactation at the time of surgery
  • Heavy smoking (>10 cigarettes per day)
  • Diabetes
  • Allergies or intolerance to ibuprofen, opioids, and local anesthetic (lidocaine and bupivacaine)
  • History of recreational drug abuse
  • History of heavy alcohol use. Substance Abuse and Mental Health Services Administration (SAMSHA)30 defines heavy alcohol use as binge drinking on 5 or more days in the past month. SAMSHA defines binge drinking as 5 or more alcoholic drinks for males or 4 or more alcoholic drinks for females on the same occasion (i.e., at the same time or within a couple of hours of each other) on at least 1 day in the past month.
  • Patients currently taking prescription pain medications or have taken over-the-counter pain medications within 4 days of surgery.
  • Patients with drug-drug or drug-disease state interactions
  • Other significant medical conditions (not reported above) that are likely to prevent the patient from going through the surgical procedure or consuming the required medications.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Univerity of Iowa College of Dentsitry Dental Clinics

    Iowa City, Iowa, 52242

Other trials in United States

About this study

Official title: Pain Management Using Pre-Emptive Analgesia in Dental Implant Surgery - A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial

To determine the clinical effectiveness of combined use of pre-emptive analgesia and long acting anesthesia for pain suppression following dental implant surgery as measured by a validated numerical rating scale and the information related to consumption of post-operative medications.

Read the detailed description

Dental practitioners often prescribe opioids for the relief of moderate - severe acute post-operative pain.1 There is evidence that alternative approaches, such as the use of long acting local anesthetics along with the combination of non-opioid analgesics such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), may prevent the need for opioid medications. With the current national opioid overdose epidemic, government officials have introduced new prescribing recommendations for the management of acute pain. Dentists can play a role to address this epidemic by wider recognition and adoption of the new prescribing recommendations for fast acting pre-emptive non-opioid analgesics to prevent acute dental pain.2 Dentists are the fifth leading prescribers of opioids among health care professionals accounting for 12% of the total immediate-release opioids prescribed in the United States (U.S).3 With the increasing trends of opioid prescribing for dental surgeries in the past few decades, dental implant procedures hold the highest increasing rate for opioid prescribing.4 In the U.S alone, there has been as many as 183,000 prescription opioid overdose related deaths from 1999 to 2015. Since 1999, the mortality rate from opioid overdose has more than quadrupled.5 With more than 650,000 opioid prescriptions being dispensed daily in the U.S,6 there has been a national call to alter the current prescribing patterns of opioids to ensure appropriate indications and patient selection.7 There are multiple adverse effects that may develop from opioid pain medications: nausea, vomiting, constipation, dizziness, headache.8 However, two major concerns associated with the excessive prescribing of opioids are overdosing leading to life threatening respiratory depression problems and the creation of an environment that fosters the development of opioid dependency, abuse and addiction.8 The U.S. Senate passed the 'Comprehensive Addiction and Recovery Act' of 2016 to combat the opioid epidemic.9 This legislation is designed to prevent opioid-related morbidity and misuse via physician and patient education, risk awareness, proper prescribing practices, and efforts to improve safer handling of prescription opioids.9 NSAIDs are widely used for their anti-inflammatory, pain and fever reducing properties. In the periphery, these drugs interfere with the formation of pro-inflammatory modulating prostaglandins and thromboxane A2 via reversible inhibition of the cyclooxygenase enzymes (Cox-1 and Cox-2). NSAIDs exact their effects through a variety of peripheral and central mechanisms. Their efficacy in the reduction of post-operative pain has been widely documented.10 It has been demonstrated that a single dose of an NSAID (i.e. etoricoxib, ketoprofen, diclofenac potassium, diflunisan, ibuprofen) may provide better acute post-operative analgesia than some commonly prescribed single dose opioids, even when they are prescribed in combination with other NSAIDs.10 There is also sound evidence that some individuals receive synergistic analgesic effects when NSAIDs are combined with acetaminophen.11 However, these effects can vary, as not everyone will achieve adequate pain relief even from the most potent drugs. Simple drug combinations of fast acting anti-inflammatories with acetaminophen can reliably provide successful analgesia for many acute pain patients in reasonably low doses.10 While modern dental literature contains numerous articles that support the tolerability, safety and efficacy of NSAIDs, many dental practices continue to prescribe opioids in cases which would likely respond better to other analgesics. Many dentists still underrate the risks and abuse of opioids. That is why it is important to design and test more lucid protocols for prescribing analgesics in dental care settings.

Severity of post-operative pain in periodontal and dental implant surgery can vary between mild to severe 12,13 and patient-reported outcome measures (PROMs) can be adverse at times.14 There is evidence that straightforward implant placement procedure is a surgical procedure associated with relatively low postoperative pain and pain management following dental implants is usually achieved by the use of drugs such as NSAIDs, acetaminophen, and/or opioids.11,15 Pre-emptive analgesia refers to the reduction of pain severity that occurs post-operatively by suppressing pain pre-emptively prior to the performance of the surgical procedure.16,17 Previous studies have shown the rationale and efficacy of using pre-emptive analgesia in periodontal and oral surgical models.18-25 Long acting local anesthetics such as bupivacaine have been shown to prolong the onset of and suppress postoperative pain better than lidocaine, an intermediate duration anesthetic.26,27 With successful pre-emptive analgesia including NSAIDs and long acting local anesthetics, the need for stronger post-operative analgesics, like opioids, may be significantly decreased.

Being tested
Ibuprofen 600 mg, Local anesthetic Group 1, Placebo oral capsule, Local anesthetic Control
Medical subject headings
Pain, Postoperative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ibuprofen 600 mgDrug

    Also called non-steroidal anti-inflammatory (NSAID)

    Ibuprofen 600mg given 30 minutes prior to beginning of surgery

  • Local anesthetic Group 1Drug

    Also called anesthesia

    0.5% bupivacaine with 1:200,000 epinephrine as the local anesthetic for Group 1 Experimental.

  • Placebo oral capsuleDrug

    Also called Placebo - Microcrystalline Cellulose NF (Avicel PH 105)

    Placebo (Microcrystalline Cellulose NF (Avicel PH 105) - compounded at the University of Iowa College of Dentistry Pharmacy) given 30 minutes prior to beginning of surgery

  • Local anesthetic ControlDrug

    Also called anesthesia

    2% lidocaine with 1:100,000 epinephrine as the local anesthetic for Group 2 - Control

Study groups in NCT03243032
Study groupRoleWhat they receive
Local Anesthetic Group 1ExperimentalGroup 1 (Pre-emptive analgesia with long acting local anesthesia - experimental group): Ibuprofen 600mg given 30 minutes prior to beginning of surgery. Surgery will be performed only using 0.5% bupivacaine with 1:200,000 epinephrine as the local anesthetic. Following the procedure, all patients will be prescribed Chlorhexidine rinse ( 0.12%) (Rinse with 15 ml two times a day and spit) for 10 days and Antibiotics: Amoxicillin 500 mg three times a day for 7 days or if allergic to penicillin, clindamycin 300 mg four times a day for 7 days. Ibuprofen (600 mg) q 6 hours: prn for pain will be provided to all patients at no charge. Tramadol 50 mg (one every 4-6 hours as needed for pain; maximum 400 mg/day) for uncontrolled pain.
Receives: Drug: Ibuprofen 600 mg; Drug: Local anesthetic Group 1
Local Anesthetic ControlPlacebo comparatorGroup 2 (Control / standard of care group): Placebo oral capsule (Microcrystalline Cellulose NF (Avicel PH 105) - compounded at the University of Iowa College of Dentistry Pharmacy) given 30 minutes prior to beginning of surgery. Surgery will be performed using 2% lidocaine with 1:100,000 epinephrine as the local anesthesia. Following the procedure, all patients will be prescribed Chlorhexidine rinse ( 0.12%) (Rinse with 15 ml two times a day and spit) for 10 days and Antibiotics: Amoxicillin 500 mg three times a day for 7 days or if allergic to penicillin, clindamycin 300 mg 4 times a day for 7 days. Ibuprofen (600 mg) q 6 hours: prn for pain will be provided to all patients at no charge. Tramadol 50 mg (one every 4-6 hours as needed for pain; maximum 400 mg/day) for uncontrolled pain.
Receives: Drug: Placebo oral capsule; Drug: Local anesthetic Control

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Post-operative pain as measured by numerical rating scale

    Difference in pain scores between test and control groups during the time points assessed (0 min, 30, 60, 90, 120, 150, 180, 210, 240 minutes and 24 hours) will be analyzed.

    Measured: 24 hours

Secondary outcomes (6)
  1. Total pain medication consumption between test and control

    Difference in pain medication consumption between test and control groups

    Measured: 14 days

  2. Time duration to take first pain medication between test and control

    Difference in the time duration to take the first post-operative pain medication between test and control groups

    Measured: 14 days

  3. Post-operative pain with anterior versus posterior site of surgery

    Within the control and test groups, correlation between sites (anterior versus posterior) and post-operative pain levels

    Measured: 24 hours

  4. Post-operative pain as it correlates with the duration of the surgical procedure

    The duration of each surgical procedure will be recorded and separate correlation analyses will be performed to assess the correlation between procedural duration and post-operative pain, within each arm of the trial.

    Measured: 24 hours

  5. Pre-surgical anxiety correlated with post-surgical pain

    Association between pre-surgical anxiety level and post-surgical pain level as measured by the pain scale within the control group, within the test group and together.

    Measured: 24 hours

  6. Complications following surgery

    Any complications encountered from medications

    Measured: 14 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Aug 2017
  2. Study start6 Oct 2017
  3. Primary completion6 Nov 2017
  4. Study completion6 Nov 2017

Why it stopped: IRB requirements to start study could not be met in a timely manner

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomized, parallel arms, double-blinded, placebo-controlled trial
Masking
Single blind
Who is masked
Participant
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03243032
Sponsor's protocol ID
201707814
Status last verified
Oct 2018
First submitted
26 Jul 2017
Last updated
12 Oct 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing Ibuprofen 600 mg and Local anesthetic Group 1 in people with Pain, Postoperative, run by Satheesh Elangovan at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 12 Oct 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Post-operative pain as measured by numerical rating scale (time frame: 24 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Oct 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in